All In Biotech

Drug Trial Radar · NCT06645691

Hyperpolarized MR Imaging With Carbon-13 Pyruvate in the Human Body

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Oct 17, 2024

Primary completion

May 31, 2028

Study completion May 31, 2028

Sponsor

Lead sponsor
National Heart Centre SingaporeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Medical Research Council (NMRC), Singapore
First posted
Oct 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 21 years, up to 99 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Positron emission tomography with 18F fluorodeoxyglucose (FDG) is the conventional imaging technique to provide information regarding tissue glucose uptake and has been highly clinically successful. However, it cannot assess downstream metabolism, which may be useful in the diagnosis and assessment of treatment response in a variety of diseases. Patients will also be exposed to ionizing radiation, the amount of exposure can vary depending on the dose of tracer administered, frequency of scans and duration of each scan. Carbon-13 (13C) magnetic resonance imaging (MRI) is particularly attractive for metabolic imaging because carbon serves as the backbone of nearly all organic molecules in the body. With this technique, the polarization increases to approximately 30%-40%, an increase of over 10,000 to 100,000-fold, thereby dramatically increasing the MRI signal . Whilst the role of 13C imaging has been demonstrated in many sites around the world, we aim to demonstrate the feasibility and application of 13C hyperpolarized imaging in healthy Singapore residents and patients with cardiovascular and/or cardiometabolic diseases.

Conditions

  • Heart Failure
  • Cardiometabolic Syndrome
  • Cancer Diagnosis
  • Cardiovascular Diseases
  • Healthy Volunteers

Interventions

  • Hyperpolarized 13C-pyruvateDrug

    Hyperpolarized 13C-pyruvate is injected intravenously at a dose of 0.43 mL/kg body weight, and at a rate of 5 mL/second followed by a 20 mL saline flush at 5 mL/second when the patient is already in the MRI scanner

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Feasibility and reproducibility of Imaging TechniqueTime frame: 30 - 45 minutes post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Heart Centre Singapore

    Singapore, Singapore · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.